|
|
|
ix | |
| Foreword |
|
xvii | |
| Preface |
|
xix | |
| Acknowledgments |
|
xxi | |
|
Section I Background epidemiology and pathology |
|
|
|
Definition and terminology of the vulnerable plaque |
|
|
3 | (10) |
|
|
|
|
|
|
|
Pathology of the vulnerable plaque |
|
|
13 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
The molecular basics of vulnerable plaque |
|
|
29 | (10) |
|
|
|
|
|
|
|
|
|
Platelets and the vulnerable plaque |
|
|
39 | (14) |
|
|
|
|
|
|
|
Role of metalloproteinases in the vulnerable plaque |
|
|
53 | (14) |
|
|
|
|
|
Oxidative stress and the vulnerable plaque |
|
|
67 | (8) |
|
|
|
|
|
Carotid vulnerable plaque |
|
|
75 | (12) |
|
|
|
|
|
Psychological triggers for plaque rupture |
|
|
87 | (16) |
|
|
|
|
|
Animal models of vulnerable plaque |
|
|
103 | (18) |
|
|
|
|
|
|
|
|
Endothelial biomarkers of vulnerable plaque progression |
|
|
121 | (20) |
|
|
|
|
|
141 | (12) |
|
|
|
|
|
Epidemiology of lipoprotein-associated phospholipase A2 |
|
|
153 | (16) |
|
|
|
|
|
Section III Invasive imaging |
|
|
|
Angiography and the vulnerable plaque |
|
|
169 | (10) |
|
|
|
|
|
Imaging the vulnerable plaque by ultrasound |
|
|
179 | (12) |
|
|
|
|
|
Intravascular palpography for vulnerable plaque assessment |
|
|
191 | (8) |
|
|
|
|
|
|
|
|
|
Diffuse reflectance near-infrared spectroscopy as a clinical technique to detect high-risk atherosclerotic plaques |
|
|
199 | (12) |
|
|
|
|
|
|
|
|
|
Optical coherence tomography |
|
|
211 | (12) |
|
|
|
|
|
|
|
223 | (10) |
|
|
|
|
|
|
|
Shear stress and the vulnerable plaque |
|
|
233 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vasa vasorum and vulnerable plaques |
|
|
245 | (10) |
|
|
|
|
|
Intravascular magnetic resonance imaging |
|
|
255 | (12) |
|
|
|
|
|
Intracoronary thermography: basic principles |
|
|
267 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Intracoronary thermography |
|
|
279 | (10) |
|
|
|
|
|
Section IV Non-invasive imaging |
|
|
|
Targeted nanoparticle contrast agents for vascular molecular imaging and therapy |
|
|
289 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Nuclear imaging of the vulnerable plaque |
|
|
303 | (10) |
|
|
|
|
|
Nanoparticle-based targeted delivery of therapeutics and non-invasive imaging of unstable endothelium |
|
|
313 | (14) |
|
|
|
|
|
|
|
|
|
Multislice computed tomography coronary plaque imaging |
|
|
327 | (8) |
|
|
|
|
|
|
|
|
|
|
|
Magnetic resonance imaging |
|
|
335 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Section V Systemic therapy |
|
|
|
Influenza vaccination as a strategy to prevent cardiovascular events |
|
|
353 | (8) |
|
|
|
|
|
|
|
361 | (10) |
|
|
|
|
|
Immunomodulation of atherosclerosis |
|
|
371 | (12) |
|
|
|
Gunilla Nordin Fredrikson |
|
|
|
|
|
|
|
|
|
|
Multifocal coronary plaque instability: evidence for a systemic inflammatory process |
|
|
383 | (16) |
|
|
|
Stem cell therapy in heart disease |
|
|
399 | (28) |
|
|
|
|
|
|
|
|
|
|
|
|
427 | (10) |
|
|
|
Stenting the vulnerable plaque |
|
|
437 | (10) |
|
|
|
|
|
Section VII Clinical management |
|
|
|
|
|
447 | (14) |
|
|
|
|
|
|
|
|
|
Regulatory issues of the Food and Drug Administration |
|
|
461 | (10) |
|
|
|
|
|
|
|
Investing in vulnerable plaque |
|
|
471 | (12) |
|
|
| Index |
|
483 | |
